Are compounds acting at metabotropic glutamate receptors the answer to treating depression?
- 15 November 2006
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 15 (12) , 1545-1553
- https://doi.org/10.1517/13543784.15.12.1545
Abstract
(2006). Are compounds acting at metabotropic glutamate receptors the answer to treating depression? Expert Opinion on Investigational Drugs: Vol. 15, No. 12, pp. 1545-1553. doi: 10.1517/13543784.15.12.1545Keywords
This publication has 78 references indexed in Scilit:
- The role ofN‐methyl‐D‐asparate receptors in neurogenesisHippocampus, 2006
- A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shellNeuroscience Letters, 2006
- Chronic Antidepressants Reduce Depolarization-Evoked Glutamate Release and Protein Interactions Favoring Formation of SNARE Complex in HippocampusJournal of Neuroscience, 2005
- Depression: a case of neuronal life and death?Biological Psychiatry, 2004
- Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039Biochemical and Biophysical Research Communications, 2004
- Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedgesBritish Journal of Pharmacology, 2001
- The olfactory bulbectomized rat as a model of depression: An updatePharmacology & Therapeutics, 1997
- Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brainJournal of Comparative Neurology, 1995
- Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramineEuropean Journal of Pharmacology: Molecular Pharmacology, 1993
- Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications.Journal of Clinical Investigation, 1991